{"entity":{"id":"nct06643793","kind":"trial","name":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","aka":[],"tldr":"A phase 2 trial of fluorouracil (5-FU), leucovorin (folinic acid) and bevacizumab (glioblastoma use) in colorectal cancer, run by Affiliated Hospital of Nantong University, now recruiting.","summary":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC is a phase 2, interventional study registered as NCT06643793 by Affiliated Hospital of Nantong University, with a registry enrolment figure of 30 participants, started 2024-11-04 and due to reach its primary completion in 2026-10-31. Interventions recorded: Irinotecan liposome (ll) + 5-FU/LV + bevacizumab. Conditions listed: Colorectal Neoplasms Malignant. Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: \"Diagnosis of colorectal cancer by histopathology and/or cytology, clinical Records showing inoperable advanced metastatic colon or rectal cancer (ie, stage IV according to the UICC AJCC TNM staging system \\[8th edition 2017\\]) ;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06643793","url":"https://clinicaltrials.gov/study/NCT06643793"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["fluorouracil","leucovorin","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06643793","phase":"2","setting":"Evaluation of Irinotecan Liposome (II) Combined With 5-fluorouracil, Leucovorin, and Bevacizumab for Second-line/Third-line Treatment of Metastatic Colorectal Cancer (mCRC): a Prospective and Exploratory Clinical Study","sponsor":"Affiliated Hospital of Nantong University","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06643793/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}